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PURPOSE: The differential diagnosis between benign and malignant adrenal cortical tumors circumscribed to the
gland is controversial. One hundred and seven patients with adrenal cortex tumors (excluding those with primary
hyperaldosteronism) were studied to assess the 5-year survival rate of adults, children, patients stratified by pathological
stage, and patients stratified according to Weiss’s score of <3 or >3.
METHODS: The patients were evaluated both clinically and biochemically. One hundred and five patients underwent
surgery and were classified pathologically as stages I, II, III, or IV. The tumors were weighed, measured, and classified
according to Weiss’s criteria and divided into 2 groups: <3 and >3.
RESULTS: After 5 years, the survival rate was 77.5% for the whole group, 74.61% for the adults, 84.3% for the children,
100% for stage I, 83.9% for stage II, 33% for stage III, and 11.7% for stage IV groups. Additionally, after 5 years, 100% of the
patients with tumors with Weiss’s score <3 were alive compared to 61.65% of those with Weiss’s score >3. The average
weights of the tumors of score <3 and >3 were 23.38 g + 41.36 g and 376.3 + 538.76 g, respectively, which is a statistically
significant difference. The average sizes of tumors of Weiss’s score <3 and >3 were 3.67 + 2.2 cm and 9.64 + 5.8 cm,
respectively, which is also a statistically significant difference.
CONCLUSIONS: Weiss’s score may be a good prognostic factor for tumors of the adrenal cortex. Additionally, there
was a statistically significant difference between the average weight and size of tumors with benign behavior (Weiss’s score
<3) and those with malignant behavior (Weiss’s score >3).
DESCRIPTORS: Adrenocortical carcinoma. Weiss’s score. Adrenocortical tumors. Adrenocortical adenomas.
Adrenal neoplasia.
Tumors arising in the adrenal cor-
tex are potentially malignant. In the
past, the majority of adrenal neo-
plasms were discovered as a result of
the symptoms caused by the growth of
the nonfunctioning tumor (pain, ab-
dominal mass, or metastases) or the
clinical picture of the functioning
tumor: primary aldosteronism, Cush-
ing’s syndrome, virilization, or
feminization either alone or in associa-
tion. At the present time, very small
nodules—either asymptomatic
(incidentalomas) or oligosymptomatic,
for which laparoscopic ablation has
shown itself to be a good option espe-
cially for benign lesions1—are discov-
ered by ultrasonography, computerized
tomography (CT), and magnetic reso-
nance imaging (MRI). Tumors not
causing symptoms and signs of adre-
nal overactivity may be biochemi-
cally functional, and those patients
who from the clinical point of view
present Cushing’s syndrome or virili-
zation may have excessive production
of both glucocorticoids and andro-
gens. The histopathological distinc-
tion between benign neoplasia (ad-
enoma) and malignant neoplasia (car-
cinoma) is very difficult to draw. There
is no question but that invasion of sur-
rounding tissue and distant metastases
define these neoplasms as carcinomas,
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but in the absence of these character-
istics, the histopathological analysis
of the adrenal tumor is controversial
and makes use of multiple histopatho-
logical criteria suggestive of malig-
nancy, though none of them is pathog-
nomonic3-5. Furthermore, each of the 3
most important reported systems has
its particular aspects, and in some
cases any one of them characterizes
the tumor as benign or indeterminate
while another may suggest malig-
nancy6. Although the size of the tumor
has been advocated as a parameter for
surgical removal, because the small
ones tend to be benign and the larger
malignant7, this criterion varies ac-
cording to the author—6 cm8, 4 cm7,
or 3 cm9—demonstrating that there is
no unanimity on this subject.
We reviewed our cases of adrenal
cortex tumors (excluding those tumors
that produced primary hyperaldos-
teronism) in order to analyze after a 5-
year follow up the overall survival
rates of adults, children, patients with
tumors of pathological stages I, II, III,
or IV in accordance with Macfarlane’s
classification10, and patients with
tumors scoring 0 to 3 and 4 to 8 on
Weiss’s scale to verify whether that
scale may be used as a prognostic fac-
tor. We also studied the correlation be-
tween the weight and size of tumors
classified between 0 and 3 and 4 and
8 according to Weiss’s score to assess
a possible significant difference be-




The records of 107 patients treated
between 1979 and 1998 were reviewed
retrospectively. In 105 of them, the his-
topathological diagnosis of adrenocor-
tical neoplasia was made in the surgi-
cal specimen. The remaining 2 patients
did not undergo surgery, and the diag-
nosis was made on the basis of the clini-
cal picture of Cushing’s syndrome with
virilization, and Cushing’s syndrome
associated with feminization in patients
with adrenal tumors seen in imaging
studies. Ninety-two patients were fe-
males, and 15 were males aged between
7 months and 69 years (median age of
29 years). Of these, 29 were below 10
years of age and were included in the
group of children. The race distribution
was white 95.5%, black 3.3%, and
Asian 1.1%.
Clinical picture
The duration of clinical history
varied from 18 days to 8 years. Clini-
cally, 40 patients presented Cushing’s
syndrome, 29 presented virilization,
27 Cushing’s syndrome with viriliza-
tion, 1 Cushing’s syndrome with
feminization, and 10 nonfunctioning
tumors, 3 of which were discovered af-
ter work up for nonspecific abdominal
pain, and 7 were discovered inciden-
tally.
Hormonal evaluation
The biochemical assessment of the
production of glucocorticoids was
made by measuring baseline urinary
cortisol and serum cortisol before and
after the administration of 2 mg of
dexamethasone. Androgen production
was assessed by measuring serum lev-
els of androstenedione, dehydro-
epiandrostenedione sulfate, and testo-
sterone. The tumors of patients with a
high basal urinary cortisol level or
those whose serum cortisol was not de-
pressed by the administration of dex-
amethasone were considered to be pro-
ducers of cortisol. The tumors of pa-
tients that presented high levels of at
least 1 of the hormones were classified
as producers of androgens. Of the 40
patients with Cushing’s syndrome, 39
(97.5%) had only cortisol-producing
tumors, and 1 (2.5%) had a cortisol-
and androgen-producing tumor. Of the
29 patients with virilization, 27 (93%)
had androgen-producing tumors, and
2 (7%) had androgen- and cortisol-pro-
ducing tumors. Of the 29 patients with
mixed clinical syndrome, 28 (96.5%)
had androgen- and cortisol-producing
tumors, and 1 had a cortisol- and
estrogen-producing tumor. Of the pa-
tients with clinically nonfunctioning
tumors, only 1 (10%) had elevated lev-
els of serum cortisol. In the other pa-
tients (90%), glucocorticoids, andro-
gens, and aldosterone were at normal
levels.
Imaging studies
Ultrasonography performed on 74
patients detected 82.4% of the primary
tumors. CT carried out on 73 patients
and MRI on 21 detected 100% of the
primary tumors with precision. Nine
patients had involvement of the infe-
rior vena cava by tumor thrombi. Ul-
trasonography revealed tumor thrombi
in 37.5% (3 out of 8), CT in 55% (5
out of 9), and MRI in 100% (4 out of
4) of the cases in which the procedure
was undertaken. Only 1 patient (0.9%)
had bilateral tumors; 47 (44%) had the
tumor on the right side, and 54 (55%)
had it on the left.
Treatment
One hundred and five patients un-
derwent surgery. The other 2 were not
candidates because they presented se-
vere respiratory insufficiency, 1 of them
with tumoral extension into the inferior
vena cava and pulmonary metastases.
The tumors of up to 5 cm in the
imaging studies were removed by
lumbotomy with resection of the 11th
rib, and those of more than 5 cm were
removed by thoracophrenolaparotomy.
Seventy-one adrenalectomies alone; 22
adrenalectomies with nephrectomies; 8
adrenalectomies with nephrectomies
and splenectomy; 1 adrenalectomy
with nephrectomy, splenectomy, and
caudal pancreatectomy; and 3 adrenal-
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ectomies with nephrectomies and par-
tial (right) hepatectomy were performed.
Only enlarged or suspected lymph
nodes were removed. No routine lym-
phadenectomies were performed.
Pathological findings
The weights of the tumors were
available in 68 cases, varying from 4
g to 2600 g (average 249 + 454 g).
Eighty-one tumors were measured, and
their sizes varied from 1.4 cm to 30 cm
(average 6.8 + 51 cm). The pathologi-
cal stage was available for 95 cases: 45
patients having stage 1 (up to 5 cm
within the capsule), 33 patients stage
II (more than 5 cm within the capsule),
3 patients stage III (any size with ext-
racapsular extension, invasion of blood
vessels, or nodes), and 24 patients
stage IV (distant metastases). Finally,
the slides were re-assessed by one and
the same pathologist (MCZ); the
tumors were classified according to
Weiss’s criteria3, which comprise 9 pa-
rameters (nuclear grade, mitotic rate,
atypical mitosis, character of cyto-
plasm, architecture of tumor cells,
necrosis, invasion of venous structures,
invasion of sinusoid structures, and in-
vasion of the capsule of tumor); and
the cases were divided into 2 groups:
Weiss’s score 0 to 3 and scores greater
than 3. The 22 patients with metastases
who underwent surgery (2 others did
not) received some kind of chemo-
therapy: preoperative mitotane (7 pa-
tients), postoperative mitotane (18 pa-
tients), and postoperative cisplatin
with etoposide (9 patients). Of these 22
patients, only 1 (a black woman)
achieved complete response with total
disappearance of pulmonary and he-
patic metastases after undergoing
adrenalectomy with nephrectomy and
caudal pancreatectomy followed by
chemotherapy using mitotane. The
postoperative exams showed a tumor
thrombus in the inferior vena cava that
had not been seen or withdrawn dur-
ing the operation and was later re-
moved during a second operation. This
patient was found free of disease at an
8-year follow-up exam.
Statistical analysis
Survival periods were estimated
from the time of treatment and were
calculated using the product-limit
method of Kaplan and Meyer11. Com-
parisons with respect to weight and
size of the tumors were performed with
the Mann-Whitney nonparametric
test12. All reported P values are 2-
tailed. P values of less than 0.05 were
taken to indicate statistically signifi-
cant differences.
RESULTS
There were no deaths in the imme-
diate postoperative period. The pa-
tients were followed up over a period
of 6 months to 240 months, and 49 of
them could be evaluated after a 5-year
period. After 5 years, 77.5% of the
whole group was alive, with the 84.3%
survival rate of the children exceeding
the 74.61% of the adults (Fig. 1). Sur-
vival rates after 5 years were stage I
patients, 100%; stage II, 83.96%; stage
III, 33%; and stage IV, 11.17% (1 pa-
tient) (Fig. 2). After 5 years, 100% of
the patients with Weiss’s scores of <3
were alive compared to 61.65% of
those with Weiss’s score of 4 to 8 (Fig.
3). The weight of 39 tumors with
Weiss’s scores of 0 to 3 varied from 2.5
g to 190 g, with an average of 23.38 ±
41.36 g and a median weight of 12 g,
whereas the weight of 31 tumors with
Weiss’s scores of 4 to 8 varied from 4
g to 2600 g with an average of 376.13
± 538.76 g and a median weight of 160
g, with a statistically significant differ-
ence between the groups (P <0.0001)
(Fig. 4). The size of 39 tumors with
Weiss’s scores of from 0 to 3 was 1 cm
to 13 cm, with an average of 3.67 ± 2.2
cm and a median size of 3 cm. The size
of 47 tumors with Weiss’s scores of 4
to 8 varied from 1.5 cm to 30 cm with
an average of 9.64 ± 5.8 cm and a me-
dian size of 9 cm, with a statistically
significant difference between the 2
groups (P <0.0001) (Fig. 5).
DISCUSSION
The normal adrenal cortex and the
adrenal tumor secrete 3 main groups of
hormones: mineralocorticoids,
glucocorticoids, and sexual hormones
Figure 1 - Kaplan-Meier Analysis of Overall Survival among 107 patients with adrenal cortical
tumor.  children,  all group, and  adults.
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than 5 cm22, there have been cases of
tumors 3 cm long23 or 40 g in weight24
that produced metastases and were
therefore correctly classified as carci-
nomas. It should be noted that in the
study mentioned above, the 40 g
tumor was initially classified incor-
rectly based on its histology as an ad-
enoma24. Neither does the functional
status serve as a prognostic factor, be-
cause patients with both functioning
and nonfunctioning carcinomas had
similar survival curves21,25. Although
the 24-hour urinary free cortisol and
serum lactate dehydrogenase levels
tended to be higher among patients
with carcinoma and Cushing’s syn-
drome, no significant statistical differ-
ence was found when comparing ad-
enomas and carcinomas16. Helicoidal
computerized tomography provides
acceptable sensitivity and specificity
in the differentiation between adeno-
mas and nonadenomas, but the lack of
long-term follow up leads to the pos-
sible persistence of diagnostic error26.
The same may be said of scintigraphy
with selenium cholesterol13. In this
study, all the patients with tumors in
the adrenal cortex—excluding those
with primary aldosteronism—that had
Weiss’s scores of less than 4 at the his-
topathological examination of the ad-
renal tumor tissue were still alive after
5 years of follow up; thus the tumors
behaved benignly as if they were true
adenomas. On the other hand, the sur-
vival curve of patients having tumors
with Weiss’s scores of 4 to 8 fell over
time, suggesting possible malignant
behavior for this group. Another inter-
esting aspect is that there was a statis-
tically significant difference between
the sizes and weights of the tumors
with Weiss’s scores of less than 4
(which behave benignly) and of those
with Weiss’s scores of 4 to 8 (which
behave with apparent malignancy),
thus supporting the idea that even
small non-functioning tumors should
be considered for laparoscopic removal
Figure 2 - Kaplan-Meier Analysis of Overall Survival among 107 patients with adrenal cortical
tumor, according to the stage.
Figure 3 - Kaplan-Meier Analysis of Overall Survival among 107 patients with adrenal cortical
tumor, according to the score of Weiss.
(androgens and estrogens). The tumors
of the glomerulosa zone, which is
physiologically responsible for aldos-
terone synthesis, behave differently
from cortical tumors: usually they are
small and functioning13 and are rarely
malignant14,15. On the other hand, cor-
tical tumors may frequently be
nonfunctioning, as is true of the
incidentalomas17, and more often than
the aldosterone-producing tumors may
behave malignantly16. For these rea-
sons, adrenocortical tumors that pro-
duce only aldosterone and which vir-
tually always have excellent progno-
sis15 have been excluded from this se-
ries. The other adrenocortical tumors
were also studied together without
separation into the so-called adenomas
and carcinomas, because it is often
difficult or even impossible to make a
differential diagnosis for neoplasms
limited to the adrenal gland6,18-20 due
to the nonuniform criteria4,5, which are
not given in detail even in recent pub-
lications13,16,21. Weight and size have
already been related to prognosis;
however, although it has been affirmed
that the majority of the adenomas
weigh less than 50 g and measure less
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Figure 4 - Figure 4 - Weight of the adrenal tumors by Weiss’s score ≤
3 and > 3. Each (•) represents one tumor
Figure 5 - Size of adrenocortical tumors by Weiss’s score ≤ 3 and > 3.
Each (•) represents one tumor
because of the slight possibility of be-
ing malignant1. As has already been re-
ported20, the children in this study sur-
vived longer on average than the
adults. The 5-year survival rate of
61.65% for our patients with Weiss’s
scores of from 4 to 8 was considerably
greater than that of the 26% to 36%
reported in contemporary reviews of
patients with carcinoma of the adrenal
cortex21,27, probably because the
unmentioned criteria for the definition
of malignancy were different. As was
to be expected, the 5-year survival
rates for stage I (100%) and stage II
(83.9%) patients who had tumors cir-
cumscribed to the adrenal gland were
considerably greater than those with
stage III (33.3%) and stage IV (11.17%)
tumors, which were certainly carcino-
mas. As others have reported28, no
standardized lymphadenectomy was
performed (only enlarged and sus-
pected lymph nodes were removed), so
the pathological staging in I and II
may not have been perfect. This may
not have influenced the outcome be-
cause lymphadenectomy has not been
shown to improve survival or decrease
recurrence27.
ACKNOWLEDGMENT
We thank Dr. João Egidio Romão
Jr., Dr. Frederico A.Q. Silva, Dra. Ana
C. Latrônico and Dr. Eder Quintão for
their substantial contributions to this
project.
RESUMO RHCFAP/3102
LUCON AM e col - Tumores do córtex
da supra-renal: resultados do trata-
mento e estudo do escore de Weiss
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OBJETIVOS: O diagnóstico dife-
rencial entre tumores benignos e ma-
lignos do córtex da supra-renal é con-
troverso. Cento e sete pacientes com
tumores do córtex da supra-renal (ex-
cluindo aqueles com hiperaldos-
ternismo primário) foram estudados
para avaliar a sobrevida em 5 anos de
adultos, de crianças e de acordo com
o estadio patológico £ 3 ou >3 segun-
do o escore de Weiss.
MÉTODOS: Os pacientes foram
avaliados clínica e laboratorialmente.
Cento e cinco pacientes foram opera-
dos e foram classificados em estadios
patológicos I, II, III ou IV. Os tumores
foram pesados, medidos, classificados
de acordo com os critérios de Weiss e
divididos em 2 grupos: ³ 3 e >3.
RESULTADOS: Após 5 anos a
sobrevida foi de 77,5% para o grupo
inteiro, 74,61% para os adultos, 84,3%
para as crianças, 100% para estadio I,
83,9% para estadio II, 33% para
estadio III e 11,7% para estadio IV.
Após 5 anos 100% dos pacientes com
tumores com escore de Weiss £ 3 esta-
vam vivos contra 61,65% dos que ti-
nham escore de Weiss >3. Os pesos
médios dos tumores com escore de
Weiss £ 3 e >3 foram de 23,38 ± 41,36
g e de 376,2 ± 538,76 g, os quais são
estatisticamente diferentes. Os tama-
nhos médios dos tumores com escore
de Weiss £ 3 e >3 foram de 3,67 ± 2,2
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cm e 9,64 ± 5,8 cm que são também
estatiscamente diferentes.
CONCLUSÃO: O escore de Weiss
pode ser um bom fator prognóstico
para tumores do córtex da supra-renal.
Há também uma diferença estatística
significante entre o peso médio e o
tamanho médio dos tumores com
comportamento benigno (escore de
Weiss ≤ 3) e aqueles com compor-
tamento maligno (escore de Weiss >3).
DESCRITORES: Tumores adre-
nocorticais. Escore de Weiss. Carci-
noma de córtex adrenal. Adenoma de
córtex adrenal. Neoplasia da supra-
renal.
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